Leigh F Johnson1, Olivia Keiser, Matthew P Fox, Frank Tanser, Morna Cornell, Chris J Hoffmann, Hans Prozesky, Andrew Boulle, Mary-Ann Davies. 1. aCentre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa bInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland cDepartment of Epidemiology, Boston University, Boston dDepartment of Global Health and Development, Boston University, Boston eHealth Economics and Epidemiology Research Office, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg fAfrica Centre for Health and Population Studies, University of KwaZulu-Natal, Durban gAurum Institute, Johannesburg, South Africa hDivision of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA iDivision of Infectious Diseases, Department of Medicine, University of Stellenbosch jTygerberg Academic Hospital, Cape Town, South Africa.
Abstract
BACKGROUND: Previous studies have reported improvements in life expectancies of patients on antiretroviral treatment (ART) over time, but it is not clear whether these improvements are explained by changes in baseline clinical characteristics, longer duration on ART or changes in clinical practices. METHOD: Two parametric survival models were fitted to mortality data from South African ART cohorts that had linked patient records to the national vital registration system. The first model estimated mortality by age, sex, cohort, baseline CD4 cell count, time since ART initiation and period of ART initiation; the second model included only age, sex, cohort and period of follow-up. Life expectancies were calculated from the estimated mortality rates. RESULTS: The first model estimated little change in mortality over time: women starting ART at age 35 years, at CD4 cell counts of 200 cells/μl or higher, had life expectancies of 32.7 years [95% confidence interval (CI): 31.6-33.6], 32.4 years (95% CI: 31.3-33.4) and 33.0 years (95% CI: 32.0-34.1) in the 2001-2006, 2007-2009 and 2010-2014 periods, respectively. However, the second model estimated a significant improvement in life expectancy; for all women on ART at age 35 years, corresponding life expectancies were 13.0 years (95% CI: 12.1-14.2), 20.4 years (95% CI: 19.5-21.4) and 26.1 years (95% CI: 25.2-26.9), respectively. CONCLUSION: Although life expectancies in South African ART patients have improved over time, these improvements are not observed after controlling for changes in baseline CD4 cell count and ART duration. This suggests that changes in clinical practice and programme scale have had little impact on ART mortality in South Africa.
BACKGROUND: Previous studies have reported improvements in life expectancies of patients on antiretroviral treatment (ART) over time, but it is not clear whether these improvements are explained by changes in baseline clinical characteristics, longer duration on ART or changes in clinical practices. METHOD: Two parametric survival models were fitted to mortality data from South African ART cohorts that had linked patient records to the national vital registration system. The first model estimated mortality by age, sex, cohort, baseline CD4 cell count, time since ART initiation and period of ART initiation; the second model included only age, sex, cohort and period of follow-up. Life expectancies were calculated from the estimated mortality rates. RESULTS: The first model estimated little change in mortality over time: women starting ART at age 35 years, at CD4 cell counts of 200 cells/μl or higher, had life expectancies of 32.7 years [95% confidence interval (CI): 31.6-33.6], 32.4 years (95% CI: 31.3-33.4) and 33.0 years (95% CI: 32.0-34.1) in the 2001-2006, 2007-2009 and 2010-2014 periods, respectively. However, the second model estimated a significant improvement in life expectancy; for all women on ART at age 35 years, corresponding life expectancies were 13.0 years (95% CI: 12.1-14.2), 20.4 years (95% CI: 19.5-21.4) and 26.1 years (95% CI: 25.2-26.9), respectively. CONCLUSION: Although life expectancies in South African ARTpatients have improved over time, these improvements are not observed after controlling for changes in baseline CD4 cell count and ART duration. This suggests that changes in clinical practice and programme scale have had little impact on ART mortality in South Africa.
Authors: Morna Cornell; Anna Grimsrud; Lara Fairall; Matthew P Fox; Gilles van Cutsem; Janet Giddy; Robin Wood; Hans Prozesky; Lerato Mohapi; Claire Graber; Matthias Egger; Andrew Boulle; Landon Myer Journal: AIDS Date: 2010-09-10 Impact factor: 4.177
Authors: Rubeena Ramjan; Alexandra Calmy; Marco Vitoria; Edward J Mills; Andrew Hill; Graham Cooke; Nathan Ford Journal: Trop Med Int Health Date: 2014-03-17 Impact factor: 2.622
Authors: Margaret May; Mark Gompels; Valerie Delpech; Kholoud Porter; Frank Post; Margaret Johnson; David Dunn; Adrian Palfreeman; Richard Gilson; Brian Gazzard; Teresa Hill; John Walsh; Martin Fisher; Chloe Orkin; Jonathan Ainsworth; Loveleen Bansi; Andrew Phillips; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin Journal: BMJ Date: 2011-10-11
Authors: Leigh F Johnson; Rob E Dorrington; Ria Laubscher; Christopher J Hoffmann; Robin Wood; Matthew P Fox; Morna Cornell; Michael Schomaker; Hans Prozesky; Frank Tanser; Mary-Ann Davies; Andrew Boulle Journal: J Int AIDS Soc Date: 2015-12-16 Impact factor: 5.396
Authors: Leigh F Johnson; Joel Mossong; Rob E Dorrington; Michael Schomaker; Christopher J Hoffmann; Olivia Keiser; Matthew P Fox; Robin Wood; Hans Prozesky; Janet Giddy; Daniela Belen Garone; Morna Cornell; Matthias Egger; Andrew Boulle Journal: PLoS Med Date: 2013-04-09 Impact factor: 11.069
Authors: Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Andrew Boulle; Michael Schomaker; Margaret T May; Robert S Hogg; Bryan E Shepherd; Susana Monge; Olivia Keiser; Fiona C Lampe; Janet Giddy; James Ndirangu; Daniela Garone; Matthew Fox; Suzanne M Ingle; Peter Reiss; Francois Dabis; Dominique Costagliola; Antonella Castagna; Kathrin Ehren; Colin Campbell; M John Gill; Michael Saag; Amy C Justice; Jodie Guest; Heidi M Crane; Matthias Egger; Jonathan A C Sterne Journal: PLoS Med Date: 2014-09-09 Impact factor: 11.069
Authors: Tali Cassidy; Morna Cornell; Bubele Makeleni; C Robert Horsburgh; Laura Trivino Duran; Virginia de Azevedo; Andrew Boulle; Matthew P Fox Journal: AIDS Behav Date: 2022-07-31
Authors: Leigh F Johnson; Margaret T May; Rob E Dorrington; Morna Cornell; Andrew Boulle; Matthias Egger; Mary-Ann Davies Journal: PLoS Med Date: 2017-12-12 Impact factor: 11.069
Authors: Morna Cornell; Leigh F Johnson; Robin Wood; Frank Tanser; Matthew P Fox; Hans Prozesky; Michael Schomaker; Matthias Egger; Mary-Ann Davies; Andrew Boulle Journal: J Int AIDS Soc Date: 2017-09-25 Impact factor: 5.396
Authors: Leigh F Johnson; Nanina Anderegg; Elizabeth Zaniewski; Jeffrey W Eaton; Peter F Rebeiro; Gabriela Carriquiry; Denis Nash; Marcel Yotebieng; Didier K Ekouevi; Charles B Holmes; Jun Y Choi; Awachana Jiamsakul; Giorgos Bakoyannis; Keri N Althoff; Annette H Sohn; Constantin Yiannoutsos; Matthias Egger Journal: AIDS Date: 2019-12-15 Impact factor: 4.177